Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Retsevmo ® ▼ (selpercatinib)
Retsevmo® ▼ (selpercatinib): RET Overview
The RET RTK has critical roles in normal kidney and enteric nervous system development and in the maintenance of several adult tissue types.
The RET RTK has critical roles in normal kidney and enteric nervous system development and in the maintenance of several adult tissue types, including
male germ cell tissues.1
The RET RTK is the receptor for ligands belonging to the GFL. The GFL are composed of GDNF, neurturin, persephin, and artemin. These ligands are not able to bind RET on their own, but require a ligand-binding subunit acting as a co-receptor, known as GFRα co-receptors. During RET activation, the GFL bind to 4 different GFRα co-receptors.1
The GFL–GFRα complex induces RET homodimerization, which activates intracellular kinase domains. This action results in RET receptor autophosphorylation and subsequent downstream activation of signal transduction pathways responsible for
RET can be altered by 2 primary mechanisms
chromosomal rearrangements that fuse the RET kinase domain with a partner protein dimerization domain producing hybrid proteins with ligand-independent activity,2-5 or
point mutations that directly or indirectly activate the RET kinase.6-8
Genetic alterations in the RET gene are implicated in the pathogenesis of several human cancers. For RET, fusions and mutations are the key alterations.7 The term RET-altered cancers encompasses RET-fusions and RET-mutations, as described in Table 1.
abnormalities that occur when the RET gene becomes fused
with another unrelated gene.
Genomic abnormalities that occur when a small change in the RET gene alters the function of the protein, causing uncontrolled cell growth.
Most common alterations
KIF5B in lung cancer
CCDC6 and NCOA4 in thyroid cancer
2% of NSCLC
10-20% of papillary and other thyroid cancers
1% of pancreatic cancer, salivary gland cancer, Spitz cancer, CRC, ovarian cancer, myeloproliferative disorder
Appears to be limited to MTC, with approximately
>60% in sporadic MTC, and
>90% in hereditary MTC.
Abbreviations: CCDC6 = coiled-coil domain containing 6; CRC = colorectal cancer; KIF5B = kinesin family member 5B; MTC = medullary thyroid cancer; NCOA4 = nuclear receptor coactivator 4; NSCLC = non-small cell lung cancer; RET = rearranged during transfection.
Figure 1. A detailed visual representation of the mechanism of disease of RET-altered cancers may be accessed by clicking here.
1. Drilon A, Hu ZI, Lai GG, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151-167. https://doi.org/10.1038/nrclinonc.2017.175
2. Romei C, Ciampi R, Elisei, R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192-202. https://doi.org/10.1038/nrendo.2016.11
3. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375-377. https://doi.org/10.1038/nm.2644
4. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381. https://doi.org/10.1038/nm.2658
5. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-384. https://doi.org/10.1038/nm.2673
6. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993;2(7):851-856. https://doi.org/10.1093/hmg/2.7.851
7. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363(6428):458-460. http://dx.doi.org/10.1038/363458a0
8. Hofstra RM, Landsvater I, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367(6461):375-376. https://doi.org/10.1038/367375a0
9. Pietrantonio F, Di Nicolantonio F, Schrock AB, et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol. 2018;29(6):1394-1401. https://dx.doi.org/10.1093/annonc/mdy090
10. Su X, He C, Ma J, et al. RET/PTC rearrangements are associated with elevated postoperative TSH levels and multifocal lesions in papillary thyroid cancer without concomitant thyroid benign disease. PLoS One. 2016;11(11):e0165596. https://dx.doi.org/10.1371/journal.pone.0165596
GDNF = glial cell derived neurotrophic factor
GFL = glial cell derived neurotrophic factor family ligands
GFRα = glial cell derived neurotrophic factor family receptor alpha
RET = rearranged during transfection
RTK = receptor tyrosine kinase
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: January 22, 2021